SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 235 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.09 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,777,493 | -5.6% | 64,472 | +3.0% | 0.26% | -0.4% |
| Q2 2023 | $1,882,177 | -17.4% | 62,614 | -0.5% | 0.26% | -19.9% |
| Q1 2023 | $2,279,084 | +2.7% | 62,906 | +1.1% | 0.32% | -3.6% |
| Q4 2022 | $2,219,138 | +5.6% | 62,213 | +0.3% | 0.33% | -8.0% |
| Q3 2022 | $2,101,000 | +22.4% | 62,054 | +4.5% | 0.36% | +12.8% |
| Q2 2022 | $1,717,000 | -7.7% | 59,354 | +3.1% | 0.32% | +4.9% |
| Q1 2022 | $1,860,000 | +17.1% | 57,563 | +5.7% | 0.31% | +15.0% |
| Q4 2021 | $1,588,000 | +11.3% | 54,456 | +1.8% | 0.27% | +2.7% |
| Q3 2021 | $1,427,000 | -9.1% | 53,509 | +5.0% | 0.26% | -6.2% |
| Q2 2021 | $1,570,000 | +19.9% | 50,981 | +2.0% | 0.28% | +15.0% |
| Q1 2021 | $1,309,000 | +6.1% | 49,981 | +1.9% | 0.24% | -4.0% |
| Q4 2020 | $1,234,000 | +20.2% | 49,039 | -0.5% | 0.25% | +4.2% |
| Q3 2020 | $1,027,000 | -2.3% | 49,275 | +11.3% | 0.24% | -7.3% |
| Q2 2020 | $1,051,000 | +45.8% | 44,257 | +10.4% | 0.26% | +16.7% |
| Q1 2020 | $721,000 | -26.2% | 40,078 | -2.7% | 0.22% | 0.0% |
| Q4 2019 | $977,000 | -8.3% | 41,204 | +6.2% | 0.22% | -12.3% |
| Q3 2019 | $1,066,000 | +3.4% | 38,799 | +24.5% | 0.25% | +2.8% |
| Q2 2019 | $1,031,000 | -24.4% | 31,164 | +41.9% | 0.25% | -25.9% |
| Q1 2019 | $1,364,000 | +49.7% | 21,968 | -19.9% | 0.33% | +21.2% |
| Q4 2018 | $911,000 | -26.8% | 27,436 | +11.1% | 0.27% | -12.7% |
| Q3 2018 | $1,244,000 | -15.4% | 24,700 | +0.5% | 0.31% | -18.2% |
| Q2 2018 | $1,471,000 | +26.8% | 24,582 | -2.9% | 0.38% | +22.7% |
| Q1 2018 | $1,160,000 | +14.7% | 25,325 | -0.2% | 0.31% | +13.8% |
| Q4 2017 | $1,011,000 | -0.7% | 25,375 | -0.3% | 0.28% | -3.8% |
| Q3 2017 | $1,018,000 | -11.0% | 25,462 | -4.1% | 0.29% | -14.6% |
| Q2 2017 | $1,144,000 | +35.5% | 26,540 | -1.6% | 0.34% | +35.1% |
| Q1 2017 | $844,000 | – | 26,961 | – | 0.25% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ASHFORD CAPITAL MANAGEMENT INC | 921,962 | $33,402,683 | 5.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 423,500 | $15,326,465 | 4.28% |
| ARMISTICE CAPITAL, LLC | 4,350,000 | $157,600,500 | 2.27% |
| S&T BANK/PA | 223,775 | $8,107 | 1.46% |
| Aristotle Capital Boston, LLC | 1,155,149 | $41,851,071 | 1.29% |
| Tributary Capital Management, LLC | 353,671 | $12,813,500 | 1.19% |
| Bridge City Capital, LLC | 62,790 | $2,274,882 | 1.14% |
| RICE HALL JAMES & ASSOCIATES, LLC | 551,285 | $19,973,056 | 1.14% |
| Intrinsic Edge Capital Management LLC | 289,704 | $10,495,976 | 1.05% |
| Parkman Healthcare Partners LLC | 131,878 | $4,777,940 | 1.04% |